Sk Biopharma Market Research Director
CurrentSK Biopharmaceuticals began research and development of new drugs in 1993 to discover the next-generation growth engine of the SK Group. Since the US FDA approved new drug candidate clinical trials in 1996, we have been focusing on the development of new synthetic drugs for the treatment of central nervous system diseases, and the whole process is carried out independently until the marketing authorization (Cenobamate) is obtained. Chemical technology export contract (Cenobamate) ▲ We have obtained technology export to the No. 1 company in the sleep disorder field and obtained FDA and EMA approval(Soliamphetol) and other research results. In addition, we have recently started research to develop treatments for brain tumors and brain metastases based on the research capabilities we have accumulated in the course of developing treatments for brain diseases.Currently, the main company, SK Biopharmaceuticals, has subsidiaries in Korea, the United States, and China to secure competitiveness as a global general pharmaceutical company. Development of innovative new drugs at the Life Science Research Institute located in Pangyo Techno Valley, Gyeonggi-dobasic research, and direct global clinical development and marketing through SK Life Sciences, a local company in New Jersey, USA. To this end, the US company employs specialists with extensive experience and competence in clinical trials, approvals and commercialization. SK Biopharmtech, a local subsidiary based in Shanghai, China, is pursuing strategic alliance opportunities in Asia.global networkSK Biopharmaceuticals has always been at the forefront of developing innovative new drugs for the global market. In the future, through the commercialization of new drugs, SK Biopharmaceuticals will achieve leapfrog development, becoming a company that covers everything from discovery of new drug candidates to marketing.
